Key result
Treatment with calcium-channel blockers in 40 patients with hypertrophic cardiomyopathy induced atrial fibrillation in 2 patients (diltiazem) and syncope in 1 patient (verapamil).
Why the study?
Do calcium-channel blockers induce adverse effects such as atrial fibrillation and syncope in patients with hypertrophic cardiomyopathy?
Observational (n=40)
Do calcium-channel blockers induce adverse effects such as atrial fibrillation and syncope in patients with hypertrophic cardiomyopathy?
Calcium-channel blockers should be used with caution in patients with obstructive hypertrophic cardiomyopathy, as their vasodilating action may increase left ventricular end-diastolic pressure and left atrial overload, risking atrial fibrillation and syncope.
No takes yet. Share an insight, caveat, or question.
CCBs may trigger AF or syncope in HCM; hypothesis-generating case data leave safety questions open for prospective study.
Doiuchi et al. (1985) conducted an observational in Hypertrophic cardiomyopathy (n=40). Calcium-channel blockers (nifedipine, diltiazem, verapamil) was evaluated on Adverse effects (atrial fibrillation and syncope). Treatment with calcium-channel blockers in 40 patients with hypertrophic cardiomyopathy induced atrial fibrillation in 2 patients (diltiazem) and syncope in 1 patient (verapamil).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: